Aravive Inc (DELISTED) (ARAV:DL)
0.0401
0.00 (0.00%)
USD |
NASDAQ |
Feb 07, 16:00
Aravive Max Drawdown (5Y)
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| January 31, 2024 | 99.73% |
| December 31, 2023 | 99.33% |
| November 30, 2023 | 99.33% |
| October 31, 2023 | 99.33% |
| September 30, 2023 | 99.33% |
| August 31, 2023 | 99.33% |
| July 31, 2023 | 99.33% |
| June 30, 2023 | 99.33% |
| May 31, 2023 | 99.33% |
| April 30, 2023 | 99.33% |
| March 31, 2023 | 99.33% |
| February 28, 2023 | 99.33% |
| January 31, 2023 | 99.33% |
| December 31, 2022 | 99.33% |
| November 30, 2022 | 99.33% |
| October 31, 2022 | 99.33% |
| September 30, 2022 | 99.33% |
| August 31, 2022 | 99.33% |
| July 31, 2022 | 99.33% |
| June 30, 2022 | 99.29% |
| May 31, 2022 | 99.19% |
| April 30, 2022 | 98.96% |
| March 31, 2022 | 98.59% |
| February 28, 2022 | 98.51% |
| January 31, 2022 | 98.45% |
| Date | Value |
|---|---|
| December 31, 2021 | 98.42% |
| November 30, 2021 | 98.42% |
| October 31, 2021 | 98.42% |
| September 30, 2021 | 98.42% |
| August 31, 2021 | 98.42% |
| July 31, 2021 | 98.42% |
| June 30, 2021 | 98.42% |
| May 31, 2021 | 98.42% |
| April 30, 2021 | 98.42% |
| March 31, 2021 | 98.42% |
| February 28, 2021 | 98.42% |
| January 31, 2021 | 98.42% |
| December 31, 2020 | 98.42% |
| November 30, 2020 | 98.42% |
| October 31, 2020 | 98.42% |
| September 30, 2020 | 98.42% |
| August 31, 2020 | 98.42% |
| July 31, 2020 | 98.42% |
| June 30, 2020 | 98.42% |
| May 31, 2020 | 98.42% |
| April 30, 2020 | 98.42% |
| March 31, 2020 | 98.42% |
| February 29, 2020 | 98.42% |
| January 31, 2020 | 98.42% |
| December 31, 2019 | 98.42% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
98.42%
Minimum
Nov 2019
99.73%
Maximum
Jan 2024
98.81%
Average
98.42%
Median
Nov 2019
Max Drawdown (5Y) Benchmarks
| Esperion Therapeutics Inc | 99.01% |
| Processa Pharmaceuticals Inc | -- |
| NovaBay Pharmaceuticals Inc | 99.98% |
| Palatin Technologies Inc | 97.38% |
| iBio Inc | 99.97% |